Sensius secures €15 million to advance breakthrough cancer thermotherapy
Sensius, a pioneer in precision thermotherapy for oncology, today announced the successful completion of a €15 million funding round enabled by GrayBella Capital and UCEA Capital Partners, with participation from the EIC Fund and a syndicate of strategic investors. The investment marks a pivotal step forward in Sensius’ mission to transform the treatment of cancer through advanced thermal technologies.
The new funding will accelerate the initiation of international clinical trials aimed at validating the efficacy and safety of Sensius’ proprietary thermotherapy platform. These trials are designed to support regulatory approvals and facilitate global market adoption. Initially targeting Head and Neck cancers—where there is an urgent need for innovative therapeutic options—Sensius’ platform is also being developed to address other critical cancer indications, including breast cancer.
“Our mission is to revolutionize patient care through advanced thermotherapy technologies,” said Paul van den Biggelaar, CEO of Sensius. “This funding brings us closer to commercializing a new standard of care—one that enhances both outcomes and quality of life for patients worldwide. We are honored by the confidence shown in us by our investors and partners.”
Richard Kivel, Managing Director at GrayBella Capital and incoming Chairman of Sensius, added: “Our investment in Sensius reflects our commitment to supporting visionary teams developing highimpact technologies. The Sensius platform represents a paradigm shift in oncology treatment, with the potential to significantly improve survival rates and reduce treatment burden.”
Joao Teixeira, Chairman of UCEA said: “We are proud to announce our investment in Sensius, a company at the forefront of innovative cancer treatment technologies. At UCEA Capital Partners, we are deeply committed to supporting visionary healthcare solutions that have the potential to transform patient outcomes on a global scale. Their groundbreaking approach to hyperthermia therapy represents a critical advancement in the fight against cancer, enhancing the efficacy of existing treatments while improving patient quality of life”.
About Sensius
Founded on technology developed at Erasmus Medical Center in Rotterdam, Sensius is developing next-generation thermotherapy systems that augment standard cancer treatments such as radiotherapy and chemotherapy. With a global footprint and strong clinical partnerships across Europe, the UK, and the United States, Sensius is dedicated to advancing therapies that deliver both
optimal clinical outcomes and improved quality of life for patients.
About GrayBella Capital (graybellacapital.com)
GrayBella Capital is a London-based venture capital firm specializing in transformative investments in life sciences and healthcare. The firm focuses on companies with scalable solutions in medical devices, digital health, AI, diagnostics, and healthcare platforms—supporting innovations that redefine patient care and improve health system efficiency.
About UCEA Capital Partners
UCEA Capital Partners is a third-generation single-family office of Portuguese origin, established in 2008 and headquartered in Mayfair, London. The firm has built a global presence with representative offices in Lisbon, Zurich, Hong Kong, Singapore, Dubai, and New York, and employs a team of over 100 professionals. Over the past three years, UCEA has analyzed and evaluated more than 250 earlystage companies.
Originally focused on real estate development in Portugal, UCEA has since adopted a global merchant bank model, combining investment, advisory, and strategic guidance. By leveraging the family’s own capital, the firm offers a bespoke and flexible model—also accessible to aligned investors—designed to deliver tailored financial solutions across sectors and geographies.
In addition, UCEA operates a dedicated, self-funded division focused on seed, Series A, and growth capital investments in four core sectors: energy, healthcare, sports, and technology.
About the EIC Fund
The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance. The European Investment Bank acts as investment adviser to the EIC Fund.
The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding. The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.
Date: June 30, 2025
Source: Sensius
